| __timestamp | Celldex Therapeutics, Inc. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 16606000 |
| Thursday, January 1, 2015 | 4011000 | 21497000 |
| Friday, January 1, 2016 | 102026000 | 25462000 |
| Sunday, January 1, 2017 | 96171000 | 28195000 |
| Monday, January 1, 2018 | 66449000 | 33078000 |
| Tuesday, January 1, 2019 | 42672000 | 36523000 |
| Wednesday, January 1, 2020 | 42534000 | 41455000 |
| Friday, January 1, 2021 | 3068000 | 74400000 |
| Saturday, January 1, 2022 | 1400000 | 101582000 |
| Sunday, January 1, 2023 | 3008000 | 112903000 |
Data in motion
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Veracyte, Inc. and Celldex Therapeutics, Inc. over the past decade. From 2014 to 2023, Veracyte, Inc. has shown a remarkable upward trajectory, with its cost of revenue increasing by approximately 580%, peaking in 2023. This reflects the company's expanding operations and market reach. In contrast, Celldex Therapeutics, Inc. experienced a more volatile pattern, with a significant drop of nearly 97% from its 2014 peak to 2022, before a slight recovery in 2023. This fluctuation may indicate strategic shifts or market challenges. Such insights are invaluable for those looking to navigate the biotech investment landscape, offering a glimpse into the financial health and strategic directions of these companies.
Cost of Revenue: Key Insights for Johnson & Johnson and Veracyte, Inc.
Cost of Revenue Trends: AstraZeneca PLC vs Celldex Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Halozyme Therapeutics, Inc. vs Celldex Therapeutics, Inc.
Analyzing Cost of Revenue: Lantheus Holdings, Inc. and Veracyte, Inc.
Cost of Revenue Comparison: Lantheus Holdings, Inc. vs Celldex Therapeutics, Inc.
Cost of Revenue Trends: Perrigo Company plc vs Celldex Therapeutics, Inc.
Cost Insights: Breaking Down Veracyte, Inc. and Viridian Therapeutics, Inc.'s Expenses
Cost of Revenue Comparison: MorphoSys AG vs Celldex Therapeutics, Inc.
Cost of Revenue: Key Insights for HUTCHMED (China) Limited and Celldex Therapeutics, Inc.
Cost of Revenue: Key Insights for Wave Life Sciences Ltd. and Celldex Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Celldex Therapeutics, Inc. vs Dyne Therapeutics, Inc.